JP2017500299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500299A5 JP2017500299A5 JP2016536776A JP2016536776A JP2017500299A5 JP 2017500299 A5 JP2017500299 A5 JP 2017500299A5 JP 2016536776 A JP2016536776 A JP 2016536776A JP 2016536776 A JP2016536776 A JP 2016536776A JP 2017500299 A5 JP2017500299 A5 JP 2017500299A5
- Authority
- JP
- Japan
- Prior art keywords
- unit
- ligand
- drug
- drug conjugate
- conjugate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918539P | 2013-12-19 | 2013-12-19 | |
| US61/918,539 | 2013-12-19 | ||
| PCT/US2014/071593 WO2015095755A1 (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
| TW103144705 | 2014-12-19 | ||
| TW103144705A TWI727919B (zh) | 2013-12-19 | 2014-12-19 | 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019041218A Division JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500299A JP2017500299A (ja) | 2017-01-05 |
| JP2017500299A5 true JP2017500299A5 (enExample) | 2018-02-01 |
| JP6701077B2 JP6701077B2 (ja) | 2020-05-27 |
Family
ID=60450371
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536776A Expired - Fee Related JP6701077B2 (ja) | 2013-12-19 | 2014-12-19 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2019041218A Active JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2020109383A Active JP7229202B2 (ja) | 2013-12-19 | 2020-06-25 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2023020516A Withdrawn JP2023055973A (ja) | 2013-12-19 | 2023-02-14 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019041218A Active JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2020109383A Active JP7229202B2 (ja) | 2013-12-19 | 2020-06-25 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2023020516A Withdrawn JP2023055973A (ja) | 2013-12-19 | 2023-02-14 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11116847B2 (enExample) |
| JP (4) | JP6701077B2 (enExample) |
| KR (3) | KR102442906B1 (enExample) |
| CN (3) | CN111558049B (enExample) |
| AU (3) | AU2014369019B2 (enExample) |
| CA (1) | CA2932647C (enExample) |
| IL (5) | IL301674A (enExample) |
| MX (2) | MX385651B (enExample) |
| NZ (1) | NZ721877A (enExample) |
| SG (1) | SG11201610465PA (enExample) |
| TW (1) | TWI727919B (enExample) |
| WO (1) | WO2015095755A1 (enExample) |
| ZA (2) | ZA201604564B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| WO2016001485A1 (en) | 2014-06-30 | 2016-01-07 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| WO2016141230A1 (en) | 2015-03-05 | 2016-09-09 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
| CA3006247A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
| CA3006242A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| EP3380126A4 (en) * | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS |
| AU2017238246B2 (en) * | 2016-03-24 | 2021-04-01 | The Administrators Of The Tulane Educational Fund | Conjugates of tacrolimus, their compositions, and their uses |
| MA43835A (fr) * | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| KR20240010534A (ko) * | 2016-08-09 | 2024-01-23 | 씨젠 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| WO2018045245A1 (en) | 2016-09-02 | 2018-03-08 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
| EA201990890A1 (ru) | 2016-10-18 | 2019-10-31 | Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида | |
| KR102617264B1 (ko) | 2016-10-19 | 2023-12-29 | 인벤라 인코포레이티드 | 항체 구조물 |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| JP7681879B2 (ja) | 2016-12-22 | 2025-05-23 | ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ | Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| WO2018124758A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| RU2022101392A (ru) | 2017-02-28 | 2022-03-02 | Иммуноджен, Инк. | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты |
| AU2018231832A1 (en) * | 2017-03-10 | 2019-08-08 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
| KR102648564B1 (ko) * | 2017-03-24 | 2024-03-19 | 씨젠 인크. | 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물 |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| IL303660A (en) * | 2017-05-02 | 2023-08-01 | Revolution Medicines Inc | Rapamycin analogs as mtor inhibitors |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
| SG11202004294XA (en) | 2017-11-29 | 2020-06-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd5+ cells |
| KR20200100113A (ko) | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
| EP3728280B1 (en) * | 2017-12-21 | 2023-06-28 | Pharmacytics B.V. | Method for improving the oral bioavailability of a drug |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| KR20200103780A (ko) * | 2018-03-09 | 2020-09-02 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 항체 접합체 |
| IL277748B2 (en) * | 2018-04-06 | 2024-07-01 | Seagen Inc | Camptothecin peptide conjugates |
| HRP20230488T1 (hr) | 2018-05-01 | 2023-08-04 | Revolution Medicines, Inc. | C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR |
| MX2020011564A (es) | 2018-05-01 | 2021-01-29 | Revolution Medicines Inc | Analogos de rapamicina unidos a c26 como inhibidores de mtor. |
| CA3099680A1 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| CN112566666A (zh) * | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| CA3102349A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| TW202519270A (zh) * | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| JP2021532116A (ja) | 2018-07-23 | 2021-11-25 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用 |
| EP3849660A1 (en) | 2018-09-12 | 2021-07-21 | QuiaPEG Pharmaceuticals AB | Releasable glp-1 conjugates |
| US20220048895A1 (en) | 2018-09-12 | 2022-02-17 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| MY208067A (en) | 2018-12-21 | 2025-04-11 | Regeneron Pharma | Tubulysins and protein-tubulysin conjugates |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| JP2022532342A (ja) | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| MY209459A (en) | 2019-07-10 | 2025-07-09 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CA3146560A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| BR112022002720A2 (pt) | 2019-08-15 | 2022-10-11 | Silverback Therapeutics Inc | Formulações de conjugados de benzazepinas e usos das mesmas |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| WO2021072330A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases |
| US20210130473A1 (en) | 2019-10-09 | 2021-05-06 | Silverback Therapeutics, Inc. | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF |
| EP4054561A4 (en) | 2019-11-08 | 2023-12-20 | North Carolina State University | Cross-linking compounds and methods of use thereof |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
| AU2020479745A1 (en) * | 2020-12-04 | 2023-07-20 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| EP4265274B1 (en) * | 2020-12-18 | 2025-03-19 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| JP7561279B2 (ja) * | 2020-12-18 | 2024-10-03 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｔｒｏｐ２を標的とする抗体薬物複合体、その製造方法及び使用 |
| WO2022136555A1 (en) | 2020-12-23 | 2022-06-30 | Ludwig-Maximilians-Universitaet Muenchen | Improved cd30 targeting antibody drug conjugates and uses thereof |
| TW202304928A (zh) | 2021-03-23 | 2023-02-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| WO2022216979A1 (en) | 2021-04-08 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| AU2022315277A1 (en) | 2021-07-19 | 2024-01-18 | Immunome, Inc. | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| JP2024540536A (ja) | 2021-11-19 | 2024-10-31 | アーディアジェン コーポレーション | Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法 |
| EP4460330A1 (en) * | 2022-01-06 | 2024-11-13 | Virtuoso Binco, Inc. | Conjugates, compositions and methods of use |
| US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
| US12539305B2 (en) | 2022-05-25 | 2026-02-03 | Revolution Medicines, Inc. | Methods of treating cancer with an mTOR inhibitor |
| US20250367307A1 (en) | 2022-06-30 | 2025-12-04 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| WO2024025396A1 (ko) * | 2022-07-28 | 2024-02-01 | 주식회사 레고켐 바이오사이언스 | 신규 오리스타틴 전구약물 |
| TW202421120A (zh) | 2022-09-09 | 2024-06-01 | 英商邁瑞科艾克斯醫藥有限公司 | 新穎化合物及其等於治療上之用途 |
| TWI903241B (zh) * | 2022-09-30 | 2025-11-01 | 美商西雅圖免疫公司 | 一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物 |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| EP4680285A1 (en) | 2023-03-13 | 2026-01-21 | Heidelberg Pharma Research GmbH | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
| KR20250074353A (ko) | 2023-11-20 | 2025-05-27 | 주식회사 에이비켐바이오 | 높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도 |
| KR20240159448A (ko) | 2023-04-28 | 2024-11-05 | 주식회사 에이비켐바이오 | 균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법 |
| KR20240159447A (ko) | 2023-04-28 | 2024-11-05 | 주식회사 에이비켐바이오 | 말레이미드 함유 링커-페이로드 접합체 |
| US20240423620A1 (en) | 2023-06-22 | 2024-12-26 | Cilag Gmbh International | Compressible surgical adjuncts, cartridges, and cartridge assemblies and methods of making surgical adjuncts |
| CN121419724A (zh) * | 2023-06-22 | 2026-01-27 | 西拉格国际有限公司 | 用于将医疗添加剂嵌入可生物吸收材料中的系统和方法 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| CN119424671A (zh) * | 2023-08-01 | 2025-02-14 | 上海新理念生物医药科技有限公司 | 含糖基吡啶型连接子的抗体药物偶联物 |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| TW202547866A (zh) | 2024-01-10 | 2025-12-16 | 丹麥商珍美寶股份有限公司 | Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法 |
| TW202545999A (zh) | 2024-02-06 | 2025-12-01 | 美商金橘生物科技公司 | 雜環綴合物及其用途 |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2026039642A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927070A (en) * | 1972-05-08 | 1975-12-16 | Karoly Szabo | M-(3,3-disubstituted ureido) phenyl {8 (substituted)methyl{9 {0 carbamates |
| US5851527A (en) | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
| EP0848957A1 (en) * | 1995-09-08 | 1998-06-24 | Kanebo Ltd. | Fas LIGAND SOLUBILIZATION INHIBITOR |
| US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| AU1607501A (en) | 1999-11-15 | 2001-05-30 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4950022B2 (ja) * | 2004-03-23 | 2012-06-13 | コンプレックス バイオシステムズ ゲーエムベーハー | 自壊性リンカーを有する高分子プロドラッグ |
| DK1912671T3 (da) * | 2005-07-18 | 2017-11-27 | Seattle Genetics Inc | Beta-glucuronid-linker-lægemiddelkonjugater |
| EP2382995A3 (en) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| TW200938223A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) |
| US20110152252A1 (en) * | 2007-12-18 | 2011-06-23 | Institut Curie | Shiga toxin b-subunit/chemotherapeutics conjugates |
| ES2547552T3 (es) | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| KR101772354B1 (ko) | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| JP5977229B2 (ja) * | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| DK2566334T3 (en) * | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| HK1207388A1 (en) | 2012-05-15 | 2016-01-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| CA2890569C (en) * | 2012-11-05 | 2019-03-05 | Pfizer Inc. | Spliceostatin analogs |
| US9695189B2 (en) | 2013-03-01 | 2017-07-04 | Mark Quang Nguyen | Chemical crosslinkers and compositions thereof |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| WO2016141230A1 (en) | 2015-03-05 | 2016-09-09 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
-
2014
- 2014-12-19 TW TW103144705A patent/TWI727919B/zh not_active IP Right Cessation
- 2014-12-19 MX MX2016007364A patent/MX385651B/es unknown
- 2014-12-19 IL IL301674A patent/IL301674A/en unknown
- 2014-12-19 JP JP2016536776A patent/JP6701077B2/ja not_active Expired - Fee Related
- 2014-12-19 KR KR1020167017938A patent/KR102442906B1/ko active Active
- 2014-12-19 CN CN202010418302.6A patent/CN111558049B/zh active Active
- 2014-12-19 KR KR1020247000133A patent/KR20240010081A/ko not_active Withdrawn
- 2014-12-19 AU AU2014369019A patent/AU2014369019B2/en active Active
- 2014-12-19 IL IL290330A patent/IL290330B2/en unknown
- 2014-12-19 SG SG11201610465PA patent/SG11201610465PA/en unknown
- 2014-12-19 CN CN201480066385.XA patent/CN105813653B/zh active Active
- 2014-12-19 CA CA2932647A patent/CA2932647C/en active Active
- 2014-12-19 NZ NZ721877A patent/NZ721877A/en unknown
- 2014-12-19 WO PCT/US2014/071593 patent/WO2015095755A1/en not_active Ceased
- 2014-12-19 US US15/106,272 patent/US11116847B2/en active Active
- 2014-12-19 CN CN202010417903.5A patent/CN111569086B/zh active Active
- 2014-12-19 KR KR1020227030682A patent/KR20220127364A/ko not_active Ceased
-
2016
- 2016-06-05 IL IL246015A patent/IL246015B/en active IP Right Grant
- 2016-06-06 MX MX2021010192A patent/MX2021010192A/es unknown
- 2016-07-05 ZA ZA2016/04564A patent/ZA201604564B/en unknown
-
2019
- 2019-03-07 JP JP2019041218A patent/JP6784790B2/ja active Active
- 2019-08-08 IL IL268595A patent/IL268595B/en active IP Right Grant
-
2020
- 2020-06-25 JP JP2020109383A patent/JP7229202B2/ja active Active
- 2020-07-06 ZA ZA2020/04099A patent/ZA202004099B/en unknown
- 2020-12-04 AU AU2020281140A patent/AU2020281140B2/en active Active
-
2021
- 2021-04-22 IL IL282581A patent/IL282581B/en unknown
- 2021-08-02 US US17/391,580 patent/US20220054650A1/en not_active Abandoned
-
2022
- 2022-12-06 AU AU2022283652A patent/AU2022283652B2/en not_active Expired - Fee Related
-
2023
- 2023-02-14 JP JP2023020516A patent/JP2023055973A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500299A5 (enExample) | ||
| RU2315782C2 (ru) | Высокомолекулярные производные камптотецинов | |
| He et al. | Rational design of a new self‐codelivery system from redox‐sensitive camptothecin–cytarabine conjugate assembly for effectively synergistic anticancer therapy | |
| Chytil et al. | New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting | |
| Zhao et al. | Novel prodrugs of SN38 using multiarm poly (ethylene glycol) linkers | |
| ES2551233T3 (es) | Métodos para la preparación de conjugados citotóxicos de maitansinoides y agentes que se fijan a las células | |
| Parrish et al. | Soluble camptothecin derivatives prepared by click cycloaddition chemistry on functional aliphatic polyesters | |
| ES2410591T3 (es) | Nuevo copolímero en bloque, preparación micelar y agente antineoplásico que lo contiene como principio activo | |
| CN101218280B (zh) | 胞苷代谢拮抗剂的聚合衍生物 | |
| CA2537336A1 (en) | Multi-arm polymer prodrugs | |
| Sedláček et al. | Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation | |
| CA2664852A1 (en) | High-molecular weight conjugate of resorcinol derivatives | |
| JP6867084B2 (ja) | 新規な陽イオン性ポリホスファゼン化合物、ポリホスファゼン−薬物コンジュゲート化合物およびその製造方法 | |
| KR20090009241A (ko) | 포도필로톡신류의 고분자 결합체 | |
| TW200836751A (en) | Polymeric derivative of nucleic acid metabolic antagonist | |
| Sharma et al. | Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene–anticancer drug conjugates | |
| US12338244B2 (en) | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | |
| WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
| WO2008076333A3 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
| KR20090066302A (ko) | 약제복합체용 블록 공중합체 및 의약조성물 | |
| KR20080106254A (ko) | 탁산류의 고분자 결합체 | |
| Williams et al. | RAFT‐Derived Polymer–Drug Conjugates: Poly (hydroxypropyl methacrylamide)(HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates | |
| Mukaya et al. | Synthesis and characterization of water-soluble polyaspartamides containing platinum (II) complex and bisphosphonate as potential antimalarial drug | |
| KR20220054368A (ko) | Dna 손상 반응의 컨쥬게이션된 억제제 | |
| JP2022501341A (ja) | ポリマーベースの高分子プロドラッグ |